This biotech stock is promising strong revenue figures and a net profit for 2020.
News & Analysis: Collegium Pharmaceutical
Buying proven businesses is better than scouring the pink sheets looking for a viable investment.
Investors are excited about the drugmaker's big formulary wins for its abuse-deterrent opioid drug.
COLL earnings call for the period ending September 30, 2019.
COLL earnings call for the period ending June 30, 2019.
COLL earnings call for the period ending March 31, 2019.
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
COLL earnings call for the period ending December 31, 2018.
The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.